Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 7, 2012, Pages 468-475

  Nguyen, Anh N ^a   Hoffman, Justin T ^a   Tsunoda, Shirley M ^a   Jang, In Jin ^b   Ma, Joseph D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Seoul National University   (South Korea)

Author keywords

CYP3A; Limited sampling strategy; Midazolam; Phenotyping

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; PLECONARIL; RIFAMPICIN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INVESTIGATIVE PROCEDURES; LIMITED SAMPLING MODEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MEASUREMENT ERROR; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; SYSTEMATIC ERROR; TANDEM MASS SPECTROMETRY;

AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; HUMANS; INJECTIONS, INTRAVENOUS; MIDAZOLAM;

EID: 84863636006     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201701     Document Type: Article

References (37)

1. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20: 342-349. doi:10.1016/S0165-6147(99)01363-2 PubMed
2. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002; 113: 746-750. doi:10.1016/S0002-9343(02)01363-3 PubMed
3. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10: 187-216. doi:10.1097/00008571- 200004000-00001 PubMed
4. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994; 4: 171-184. doi:10.1097/00008571-199408000-00001 PubMed
5. Eap CB, Fellay J, Buclin T, Bleiber G, Golay KP, Brocard M, Baumann P, Telenti A. CYP3A activity measured by the midazolam test is not related to 3435 C > T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics. 2004; 14: 255-260. doi:10.1097/00008571-200404000-00005 PubMed
6. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM et al. Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003; 43: 443-469. PubMed
7. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981; 30: 653-661. doi:10.1038/clpt.1981.217 PubMed
8. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994; 47: 1643-1653. doi:10.1016/0006-2952(94)90543-6 PubMed
9. Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther. 2011; 90: 100-108. doi:10.1038/clpt.2011.59 PubMed
10. Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004; 76: 452-466. doi:10.1016/j.clpt.2004.07.006 PubMed
11. Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and non-invasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol. 2005; 45: 1187-1197. doi:10.1177/0091270005280077 PubMed
12. Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002; 42: 376-382. doi:10.1177/0091270002424002 PubMed
13. Rogers JF, Nafziger AN, Kashuba AD, Streetman DS, Rocci ML Jr, Choo EF, Wilkinson GR, Bertino JS Jr. Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam: midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol. 2002; 42: 1079-1082. doi:10.1177/009127002401382614 PubMed
14. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003; 74: 437-447. doi:10.1016/S0009-9236(03)00229-7 PubMed
15. Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr. Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. Br J Clin Pharmacol. 2009; 67: 374-375. doi:10.1111/j.1365-2125.2008.03361.x PubMed
16. Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS Jr. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol. 2006; 46: 103-108. doi:10.1177/0091270005283286 PubMed
17. Majumdar AK, Yan KX, Selverian DV, Barlas S, Constanzer M, Dru J, McCrea JB, Ahmed T, Frick GS, Kraft WK, Petty KJ, Greenberg HE. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol. 2007; 47: 744-750. doi:10.1177/0091270007300807 PubMed
18. Rogers JF, Morrison AL, Nafziger AN, Jones CL, Rocci ML Jr, Bertino JS Jr. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther. 2002; 72: 711-717. doi:10.1067/mcp.2002. 128866 PubMed
19. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999; 66: 461-471. doi:10.1016/S0009-9236(99)70009-3 PubMed
20. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010; 30: 136-143. doi:10.1592/phco.30.2.136 PubMed
21. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004; 76: 104-112. doi:10.1016/j.clpt.2004.03.009 PubMed
22. Tham LS, Lee HS, Wang L, Yong WP, Fan L, Ong AB, Sukri N, Soo R, Lee SC, Goh BC. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Ther Drug Monit. 2006; 28: 255-261. doi:10.1097/01.ftd.000?01?944? 97.55269.d9 PubMed
23. Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010; 88: 499-505. doi:10.1038/clpt.2010.119 PubMed
24. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003; 74: 150-156. doi:10.1016/S0009-9236(03)00123-1 PubMed
25. Nakamoto T, Hase I, Imaoka S, Hiroi T, Oda Y, Asada A, Funae Y. Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin. Pharmacogenetics. 2000; 10: 571-575. doi:10.1097/00008571-200008000-00011 PubMed
26. Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS Jr. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos. 2006; 34: 783-785. doi:10.1124/dmd.105.007831 PubMed
27. Ignjatovic AR, Miljkovic B, Todorovic D, Timotijevic I, Pokrajac M. Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients. J Clin Pharmacol. 2011; 51: 661-671. doi:10.1177/0091270010372105 PubMed
28. Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol. 2011; 71: 88-94. doi:10.1111/j.1365-2125.2010. 03802.x PubMed
29. Ma JD, Nguyen ET, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Lee LS. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2010; 48: 847-853. PubMed
30. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation. 1995; 59: 505-511. PubMed
31. Meier-Kriesche HU, Alloway R, Gaber AO, Canafax DM, Kaplan B. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. J Clin Pharmacol. 1999; 39: 166-171. doi:10.1177/00912709922007723 PubMed
32. Gaspari F, Perico N, Signorini O, Caruso R, Remuzzi G. Abbreviated kinetic profiles in area-under- the-curve monitoring of cyclosporine therapy. Technical note. Kidney Int. 1998; 54: 2146-2150. doi:10.1046/j.1523-1755.1998. 00194.x PubMed
33. Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther. 2005; 78: 529-539. doi:10.1016/j.clpt.2005. 08.004 PubMed
34. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE. Invivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001; 11: 781-791. doi:10.1097/00008571-200112000-00006 PubMed
35. Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey RT Jr. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol. 2008; 48: 671-680. doi:10.1177/0091270008317305 PubMed
36. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1: 307-310. doi:10.1016/S0140-6736(86)90837-8 PubMed
37. Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH. Single plasma sampling to predict oral clearance of CYP3A probe midazolam. Acta Pharmacol Sin. 2001; 22: 634-638. PubMed